<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00312377</url>
  </required_header>
  <id_info>
    <org_study_id>D4200C00032</org_study_id>
    <secondary_id>6474IL/0032</secondary_id>
    <secondary_id>2005-004749-32</secondary_id>
    <nct_id>NCT00312377</nct_id>
  </id_info>
  <brief_title>ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer</brief_title>
  <acronym>ZODIAC</acronym>
  <official_title>A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination With ZD6474 (ZACTIMA™) Versus Docetaxel (TAXOTERE™) With Placebo in Subjects With Locally Advanced or Metastatic NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      This large phase III clinical study is studying the effect of vandetanib (ZACTIMA) in
      treating non-small cell lung cancer (NSCLC). Vandetanib is a new type of agent that targets
      the blood supply to a cancer tumour (through it's anti-vascular endothelial growth factor
      receptor (VEGFR) properties) and the tumour cells themselves (through it's anti-endothelial
      growth factor receptor (EGFR) actions). This study will look at the effects of vandetanib in
      lung cancer patients who have had their cancer re-appear after treatment with standard
      chemotherapy.

      This clinical study will test if the vandetanib anti-VEGF and anti-EGFR characteristics can
      deliver longer improved progression free survival and improved overall survival than
      docetaxel (Taxotere) alone.

      All patients participating this clinical study will receive treatment with docetaxel, a
      commonly used treatment for recurrent non-small cell lung cancer.

      In addition, some patients will also receive vandetanib (ZACTIMA), an anti-EGFR / anti-VEGF
      agent.

      Recent clinical research shows that vascular endothelial growth factor receptor (VEGFR)
      inhibition, when used with standard chemotherapy, can lead to increased survival in advanced
      non-small cell lung cancer (NSCLC) patients.

      Other research shows that epidermal growth factor receptor (EGFR) inhibitors, like erlotinib
      (Tarceva) can also increase overall non-small cell lung cancer survival by killing tumour
      cells and stopping them from dividing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) in the Overall Population</measure>
    <time_frame>RECIST tumour assessments carried out every 6 weeks from randomisation until the date of first documented objective disease progression or date of death from any cause, whichever came first assessed up to 24 months</time_frame>
    <description>Median time (in weeks) from randomisation until objective disease progression or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment. Progression was derived according to RECIST 1.0 and is defined as an increase of at least 20% in the total tumour size of measurable lesions over the nadir measurement, unequivocal progression in the non-target lesions or the appearance of one or more new lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) in the Female Population</measure>
    <time_frame>RECIST tumour assessments carried out every 6 weeks from randomisation until the date of first documented objective disease progression or date of death from any cause, whichever came first assessed up to 24 months</time_frame>
    <description>Median time (in weeks) from randomisation until objective disease progression or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment. Progression was derived according to RECIST 1.0 and is defined as an increase of at least 20% in the total tumour size of measurable lesions over the nadir measurement, unequivocal progression in the non-target lesions or the appearance of one or more new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in the Overall Population</measure>
    <time_frame>Time to death in months</time_frame>
    <description>Overall survival is defined as the time from date of randomization until death. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive (ie their status must be known at the censored date and should not be lost to follow up or unknown).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in the Female Population</measure>
    <time_frame>Time to death in months</time_frame>
    <description>Overall survival is defined as the time from date of randomization until death. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive (ie their status must be known at the censored date and should not be lost to follow up or unknown).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Each patient was assessed for objective response from the sequence of RECIST scan data up to data cut off. RECIST tumour assessments carried out every 6 weeks from randomisation until objective progression</time_frame>
    <description>The ORR is the number of patients that are responders ie those patients with a confirmed best objective response of complete response (CR) or partial response (PR) as determined according to RECIST 1.0. CR is defined as the disappearance of all target lesions with no evidence of tumour elsewhere and PR is defined as at least a 30% reduction in the total tumour size of measurable lesions with no new lesions and no progression in the non-target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>RECIST tumour assessments carried out every 6 weeks from randomisation until objective progression</time_frame>
    <description>Disease control rate is defined as the number of patients who achieved disease control at least 6 weeks following randomisation. Disease control at 6 weeks is defined as a best objective response of complete response (CR), partial response (PR) or stable disease (SD) &gt;= 6 weeks as determined according to RECIST 1.0. CR is defined as the disappearance of all target lesions with no evidence of tumour elsewhere, PR is defined as at least a 30% reduction in the total tumour size of measurable lesions with no new lesions and no progression in the non-target lesions and SD &gt;= 6 is assigned to patients who have not responded and have no evidence of progression at least 6 weeks after randomisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>RECIST tumour assessments carried out every 6 weeks from randomisation until objective progression</time_frame>
    <description>Response is defined as a confirmed best objective response of CR or PR. Duration of response is defined as time from the date of first documented response until date of documented progression or death in the absence of disease progression (provided death is within 3 months of last RECIST assessment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration of Disease-related Symptoms (TDS) by Functional Assessment of Cancer Therapy - Lung (FACT-L) Lung Cancer Subscale (LCS).</measure>
    <time_frame>FACT-L questionnaires are to be administered every 3 weeks after randomisation</time_frame>
    <description>The lung cancer subscale (LCS) consists of 7 items of the FACT-L (3 items relating to breathing/dyspnea, and 1 item each relating to cough, weight loss, appetite, and cognition). The LCS total score is the sum of the scores from the 7 items.
Time to deterioration is defined as the interval from the date of randomization to the first assessment of worsened without an improvement in the next 21 days.
A patient will be defined as having a deterioration in symptoms if they have a single visit assessment of 'worsened' with no visit assessment of 'improved' within the next 21 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration of Disease-related Symptoms (TDS) by FACT-L Pulmonary Symptom Index (PSI)</measure>
    <time_frame>FACT-L questionnaires are to be administered every 3 weeks after randomisation</time_frame>
    <description>The pulmonary symptom index (PSI) consists of 4 items of the LCS relating to pulmonary symptoms (i.e. 3 items relating to breathing/dyspnea, and 1 item relating to cough). The PSI score is the sum of the scores from the 4 items.
Time to deterioration is defined as the interval from the date of randomization to the first assessment of worsened without an improvement in the next 21 days.
A patient will be defined as having a deterioration in symptoms if they have a single visit assessment of 'worsened' with no visit assessment of 'improved' within the next 21 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1690</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vandetanib + Docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>infusion</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>TAXOTERE™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vandetanib</intervention_name>
    <description>oral</description>
    <arm_group_label>2</arm_group_label>
    <other_name>ZACTIMA™</other_name>
    <other_name>ZD6474</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Lung cancer patients who answer true to the following statements are eligible to join this
        clinical study.

          -  I have a confirmed diagnosis of locally advanced or metastatic non small cell lung
             cancer (Stage IIIb - IV)

          -  I have had 1st line anti-cancer therapy. Previous treatment with Avastin (bevacizumab)
             in first line NSCLC is allowed.

        Exclusion Criteria:

        Lung cancer patients who answer true to the following are NOT eligible to join this
        clinical study.

          -  I do not have non small cell lung cancer (NSCLC)

          -  I have received treatment with docetaxel (Taxotere). Prior treatment with paclitaxel
             is acceptable.

          -  I have received 2nd line anti-cancer therapy (For example, patients with previous 2nd
             line non small cell lung cancer (NSCLC) treatment with Tarceva (erlotinib, OSI-744),
             Alimta (pemetrexed) are not eligible)

          -  I have been treated with VEGFR-tyrosine kinase inhibitors (TKIs) (sunitinib,
             sorafenib, other VEGF TKIs). Previous treatment with Avastin (bevacizumab) in 1st line
             non small cell lung cancer is permitted.

          -  I have a history of uncontrolled irregular heartbeat

          -  I have a history of high blood pressure which has not been controlled with medication
             If you are unsure of the meaning of the inclusion and exclusion criteria above, please
             contact the call center number for help.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Contact-US@sanofi.com</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hutchinson</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Armonk</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bahía Blanca</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grimmenstein</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels (Jette)</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels (Woluwé-St-Lambert)</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fortaleza</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goiânia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>København Ø</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boulogne Billancourt</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caen Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Herblain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bad Berka</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vellore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jakarta Timur</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yogyakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mantova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Akashi-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Isehara-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koto-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kumamoto-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsuyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Okayama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Okazaki-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osakasayama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sakai-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sunto-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyonaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ube-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Utsunomiya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kubang Kerian</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nilai</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Penang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durango</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morelia</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toluca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Funchal</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanoi city</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ho Chi Minh city</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Indonesia</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United States</country>
    <country>Vietnam</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=340&amp;filename=CSR-D4200C00032.pdf</url>
    <description>CSR-D4200C00032.pdf</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=340&amp;filename=vandetanib_Study_32_ZODIAC_CSP_Redacted.pdf</url>
    <description>CSP Redacted</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2006</study_first_submitted>
  <study_first_submitted_qc>April 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2006</study_first_posted>
  <results_first_submitted>April 27, 2011</results_first_submitted>
  <results_first_submitted_qc>April 27, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 24, 2011</results_first_posted>
  <last_update_submitted>August 24, 2016</last_update_submitted>
  <last_update_submitted_qc>August 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled 08 May 2006, last patient enrolled 14 March 2008, cut off date 22 August 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vandetanib 100 mg Plus Docetaxel</title>
          <description>Vandetanib 100 mg oral tablet taken once daily in combination with docetaxel 75 mg/m2 IVb infusion every 21 days up to a maximum of 6 cycles</description>
        </group>
        <group group_id="P2">
          <title>Placebo Plus Docetaxel</title>
          <description>Placebo tablet taken once daily plus docetaxel 75 mg/m2 IVb infusion every 21 days up to a maximum of 6 cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="694">randomised patients</participants>
                <participants group_id="P2" count="697">randomised patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50">ongoing study treatment at data cut-off</participants>
                <participants group_id="P2" count="29">ongoing study treatment at data cut-off</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="644"/>
                <participants group_id="P2" count="668"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="403"/>
                <participants group_id="P2" count="418"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomised but never received treatment</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinue treatment survival follow up</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="200"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site ended participation in study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vandetanib 100 mg Plus Docetaxel</title>
          <description>Vandetanib 100 mg plus docetaxel</description>
        </group>
        <group group_id="B2">
          <title>Placebo Plus Docetaxel</title>
          <description>Placebo plus docetaxel</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="694"/>
            <count group_id="B2" value="697"/>
            <count group_id="B3" value="1391"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" lower_limit="28" upper_limit="82"/>
                    <measurement group_id="B2" value="58.4" lower_limit="20" upper_limit="82"/>
                    <measurement group_id="B3" value="58.45" lower_limit="20" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="497"/>
                    <measurement group_id="B2" value="473"/>
                    <measurement group_id="B3" value="970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS) in the Overall Population</title>
        <description>Median time (in weeks) from randomisation until objective disease progression or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment. Progression was derived according to RECIST 1.0 and is defined as an increase of at least 20% in the total tumour size of measurable lesions over the nadir measurement, unequivocal progression in the non-target lesions or the appearance of one or more new lesions.</description>
        <time_frame>RECIST tumour assessments carried out every 6 weeks from randomisation until the date of first documented objective disease progression or date of death from any cause, whichever came first assessed up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib 100 mg Plus Docetaxel</title>
            <description>Vandetanib 100 mg plus docetaxel</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Docetaxel</title>
            <description>Placebo plus docetaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) in the Overall Population</title>
          <description>Median time (in weeks) from randomisation until objective disease progression or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment. Progression was derived according to RECIST 1.0 and is defined as an increase of at least 20% in the total tumour size of measurable lesions over the nadir measurement, unequivocal progression in the non-target lesions or the appearance of one or more new lesions.</description>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="694"/>
                <count group_id="O2" value="697"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="15" upper_limit="18"/>
                    <measurement group_id="O2" value="14" lower_limit="12.7" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS) in the Female Population</title>
        <description>Median time (in weeks) from randomisation until objective disease progression or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment. Progression was derived according to RECIST 1.0 and is defined as an increase of at least 20% in the total tumour size of measurable lesions over the nadir measurement, unequivocal progression in the non-target lesions or the appearance of one or more new lesions.</description>
        <time_frame>RECIST tumour assessments carried out every 6 weeks from randomisation until the date of first documented objective disease progression or date of death from any cause, whichever came first assessed up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib 100 mg Plus Docetaxel</title>
            <description>Vandetanib 100 mg plus docetaxel</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Docetaxel</title>
            <description>Placebo plus docetaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) in the Female Population</title>
          <description>Median time (in weeks) from randomisation until objective disease progression or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment. Progression was derived according to RECIST 1.0 and is defined as an increase of at least 20% in the total tumour size of measurable lesions over the nadir measurement, unequivocal progression in the non-target lesions or the appearance of one or more new lesions.</description>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" lower_limit="17.9" upper_limit="23.9"/>
                    <measurement group_id="O2" value="18.3" lower_limit="15" upper_limit="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) in the Overall Population</title>
        <description>Overall survival is defined as the time from date of randomization until death. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive (ie their status must be known at the censored date and should not be lost to follow up or unknown).</description>
        <time_frame>Time to death in months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib 100 mg Plus Docetaxel</title>
            <description>Vandetanib 100 mg plus docetaxel</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Docetaxel</title>
            <description>Placebo plus docetaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) in the Overall Population</title>
          <description>Overall survival is defined as the time from date of randomization until death. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive (ie their status must be known at the censored date and should not be lost to follow up or unknown).</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="694"/>
                <count group_id="O2" value="697"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="9.6" upper_limit="11.5"/>
                    <measurement group_id="O2" value="10" lower_limit="9.2" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) in the Female Population</title>
        <description>Overall survival is defined as the time from date of randomization until death. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive (ie their status must be known at the censored date and should not be lost to follow up or unknown).</description>
        <time_frame>Time to death in months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib 100 mg Plus Docetaxel</title>
            <description>Vandetanib 100 mg plus docetaxel</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Docetaxel</title>
            <description>Placebo plus docetaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) in the Female Population</title>
          <description>Overall survival is defined as the time from date of randomization until death. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive (ie their status must be known at the censored date and should not be lost to follow up or unknown).</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="10.5" upper_limit="17.1"/>
                    <measurement group_id="O2" value="14.2" lower_limit="10.8" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>The ORR is the number of patients that are responders ie those patients with a confirmed best objective response of complete response (CR) or partial response (PR) as determined according to RECIST 1.0. CR is defined as the disappearance of all target lesions with no evidence of tumour elsewhere and PR is defined as at least a 30% reduction in the total tumour size of measurable lesions with no new lesions and no progression in the non-target lesions.</description>
        <time_frame>Each patient was assessed for objective response from the sequence of RECIST scan data up to data cut off. RECIST tumour assessments carried out every 6 weeks from randomisation until objective progression</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib 100 mg Plus Docetaxel</title>
            <description>Vandetanib 100 mg plus docetaxel</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Docetaxel</title>
            <description>Placebo plus docetaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>The ORR is the number of patients that are responders ie those patients with a confirmed best objective response of complete response (CR) or partial response (PR) as determined according to RECIST 1.0. CR is defined as the disappearance of all target lesions with no evidence of tumour elsewhere and PR is defined as at least a 30% reduction in the total tumour size of measurable lesions with no new lesions and no progression in the non-target lesions.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="694"/>
                <count group_id="O2" value="697"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR)</title>
        <description>Disease control rate is defined as the number of patients who achieved disease control at least 6 weeks following randomisation. Disease control at 6 weeks is defined as a best objective response of complete response (CR), partial response (PR) or stable disease (SD) &gt;= 6 weeks as determined according to RECIST 1.0. CR is defined as the disappearance of all target lesions with no evidence of tumour elsewhere, PR is defined as at least a 30% reduction in the total tumour size of measurable lesions with no new lesions and no progression in the non-target lesions and SD &gt;= 6 is assigned to patients who have not responded and have no evidence of progression at least 6 weeks after randomisation.</description>
        <time_frame>RECIST tumour assessments carried out every 6 weeks from randomisation until objective progression</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib 100 mg Plus Docetaxel</title>
            <description>Vandetanib 100 mg plus docetaxel</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Docetaxel</title>
            <description>Placebo plus docetaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR)</title>
          <description>Disease control rate is defined as the number of patients who achieved disease control at least 6 weeks following randomisation. Disease control at 6 weeks is defined as a best objective response of complete response (CR), partial response (PR) or stable disease (SD) &gt;= 6 weeks as determined according to RECIST 1.0. CR is defined as the disappearance of all target lesions with no evidence of tumour elsewhere, PR is defined as at least a 30% reduction in the total tumour size of measurable lesions with no new lesions and no progression in the non-target lesions and SD &gt;= 6 is assigned to patients who have not responded and have no evidence of progression at least 6 weeks after randomisation.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="694"/>
                <count group_id="O2" value="697"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413"/>
                    <measurement group_id="O2" value="380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DoR)</title>
        <description>Response is defined as a confirmed best objective response of CR or PR. Duration of response is defined as time from the date of first documented response until date of documented progression or death in the absence of disease progression (provided death is within 3 months of last RECIST assessment)</description>
        <time_frame>RECIST tumour assessments carried out every 6 weeks from randomisation until objective progression</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib 100 mg Plus Docetaxel</title>
            <description>Vandetanib 100 mg plus docetaxel</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Docetaxel</title>
            <description>Placebo plus docetaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DoR)</title>
          <description>Response is defined as a confirmed best objective response of CR or PR. Duration of response is defined as time from the date of first documented response until date of documented progression or death in the absence of disease progression (provided death is within 3 months of last RECIST assessment)</description>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="694"/>
                <count group_id="O2" value="697"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" lower_limit="7.14" upper_limit="72.29"/>
                    <measurement group_id="O2" value="19.7" lower_limit="9.71" upper_limit="41.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Deterioration of Disease-related Symptoms (TDS) by Functional Assessment of Cancer Therapy - Lung (FACT-L) Lung Cancer Subscale (LCS).</title>
        <description>The lung cancer subscale (LCS) consists of 7 items of the FACT-L (3 items relating to breathing/dyspnea, and 1 item each relating to cough, weight loss, appetite, and cognition). The LCS total score is the sum of the scores from the 7 items.
Time to deterioration is defined as the interval from the date of randomization to the first assessment of worsened without an improvement in the next 21 days.
A patient will be defined as having a deterioration in symptoms if they have a single visit assessment of ‘worsened’ with no visit assessment of ‘improved’ within the next 21 days.</description>
        <time_frame>FACT-L questionnaires are to be administered every 3 weeks after randomisation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib 100 mg Plus Docetaxel</title>
            <description>Vandetanib 100 mg plus docetaxel</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Docetaxel</title>
            <description>Placebo plus docetaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Deterioration of Disease-related Symptoms (TDS) by Functional Assessment of Cancer Therapy - Lung (FACT-L) Lung Cancer Subscale (LCS).</title>
          <description>The lung cancer subscale (LCS) consists of 7 items of the FACT-L (3 items relating to breathing/dyspnea, and 1 item each relating to cough, weight loss, appetite, and cognition). The LCS total score is the sum of the scores from the 7 items.
Time to deterioration is defined as the interval from the date of randomization to the first assessment of worsened without an improvement in the next 21 days.
A patient will be defined as having a deterioration in symptoms if they have a single visit assessment of ‘worsened’ with no visit assessment of ‘improved’ within the next 21 days.</description>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="694"/>
                <count group_id="O2" value="697"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="6.1" upper_limit="82.3"/>
                    <measurement group_id="O2" value="11.9" lower_limit="6.0" upper_limit="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Deterioration of Disease-related Symptoms (TDS) by FACT-L Pulmonary Symptom Index (PSI)</title>
        <description>The pulmonary symptom index (PSI) consists of 4 items of the LCS relating to pulmonary symptoms (i.e. 3 items relating to breathing/dyspnea, and 1 item relating to cough). The PSI score is the sum of the scores from the 4 items.
Time to deterioration is defined as the interval from the date of randomization to the first assessment of worsened without an improvement in the next 21 days.
A patient will be defined as having a deterioration in symptoms if they have a single visit assessment of ‘worsened’ with no visit assessment of ‘improved’ within the next 21 days.</description>
        <time_frame>FACT-L questionnaires are to be administered every 3 weeks after randomisation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib 100 mg Plus Docetaxel</title>
            <description>Vandetanib 100 mg plus docetaxel</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Docetaxel</title>
            <description>Placebo plus docetaxel</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Deterioration of Disease-related Symptoms (TDS) by FACT-L Pulmonary Symptom Index (PSI)</title>
          <description>The pulmonary symptom index (PSI) consists of 4 items of the LCS relating to pulmonary symptoms (i.e. 3 items relating to breathing/dyspnea, and 1 item relating to cough). The PSI score is the sum of the scores from the 4 items.
Time to deterioration is defined as the interval from the date of randomization to the first assessment of worsened without an improvement in the next 21 days.
A patient will be defined as having a deterioration in symptoms if they have a single visit assessment of ‘worsened’ with no visit assessment of ‘improved’ within the next 21 days.</description>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="694"/>
                <count group_id="O2" value="697"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" lower_limit="5.9" upper_limit="36.7"/>
                    <measurement group_id="O2" value="11.9" lower_limit="6" upper_limit="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vandetanib 100 mg Plus Docetaxel</title>
          <description>Vandetanib 100 mg plus docetaxel</description>
        </group>
        <group group_id="E2">
          <title>Placebo Plus Docetaxel</title>
          <description>Placebo plus docetaxel</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="263" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="232" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bone Marrow Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Febrile Bone Marrow Aplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Second Degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardiac Tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ventricular Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hereditary Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness Unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular Surface Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Retinal Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Appendicitis Perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastric Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ileus Paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lower Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Oesophageal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Oesophageal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Proctitis Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Performance Status Decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Systemic Inflammatory Response Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Neutropenic Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bacterial Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Catheter Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Central Line Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Infective Exacerbation Of Chronic Obstructive Airways Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Infective Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lung Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Oesophageal Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Perianal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pneumocystis Jiroveci Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pneumonia Streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rash Pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rectal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Skin Bacterial Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Brain Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Facial Bones Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Multiple Fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Radiation Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Skin Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Skull Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Blood Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Blood Pressure Orthostatic Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T Wave Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Failure To Thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Metastatic Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Myelodysplastic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Loss Of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Altered State Of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Brachial Plexopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cauda Equina Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cerebral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Coma Hepatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pyramidal Tract Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Spinal Cord Compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Psychotic Behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pulmonary Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Cryptogenic Organising Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Diaphragmatic Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hydropneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Laryngeal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Lung Infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pulmonary Alveolar Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Respiratory Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Photosensitivity Reaction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Toxic Epidermal Necrolysis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dermatitis Exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Drug Eruption</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rash Erythematous</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Toxic Skin Eruption</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Erythema Multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Exfoliative Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Palmar-Plantar Erythrodysaesthesia Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Rash Maculo-Papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Skin Toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Telangiectasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Subclavian Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Superior Vena Caval Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vena Cava Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="637" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="630" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="212" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="174" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="284" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="218" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="158" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="221" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="208" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="199" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="204" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="282" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="166" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="230" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="240" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Nail Disorder</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="697"/>
              </event>
              <event>
                <sub_title>Photosensitivity Reaction</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="694"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="697"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi</organization>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

